Mediclinic Cape Town has introduced the new BioJet 3-D MRI Fusion Prostate Biopsy System to detect male cancers – testicular and prostate – earlier than what was previously possible.
Early and accurate detection of prostate cancer is essential for doctors to provide the most appropriate treatment plans for the disease.
“Previously we were missing 50 – 80% of significant cancers and over diagnosing low risk cancers that did not require treatment, said Urologist at Mediclinic Cape Town, Dr Werner Botha.
“We are now identifying 40% more aggressive cancers earlier and detecting less of the insignificant lesions,” continued Dr Botha.
The Biojet MRI Fusion is an advanced navigation platform that enables an accurate detection of suspicious lesions by combining MRI and real-time Ultrasound. Biojet MRI Fusion enables enhanced detection and control of regions of interest and can reach MRI visible tumours with high precision.
“The MRI prostate results are incorporated into the Biojet Fusion software programme where the lesions are mapped out. On the day of the biopsy the MRI mapping is fused with the results from the trans rectal ultrasound, providing an accurate target area,” explained Dr Botha.
It is a safe and a more effective alternative to a standard ultrasound guided prostate biopsy, which can miss significant lesions and consequently lead to an underestimation of the patient’s clinical situation.
Similar systems are available but many are cumbersome and require biopsy via the rectum, which leads to additional potential for infection. The Biojet MRI Fusion only requires a laptop with the Biojet software and a special electronic stepper that holds the transrectal ultrasound.
A ‘grid’ is placed over the patient’s perineal area and coordinates are used to locate the cancer area, similar to a GPS tracker. As a result, the urologist can perform this procedure on his own and does not require a technician in theatre.
According to Dr Botha, this new technology improves diagnostic accuracy and enhances detection of suspicious lesions. A further advantage is the reproducible nature of the biopsies for active surveillance of tumours or lesions, allowing doctors to monitor and track the progression of the cancer or success of the treatment.
“Our patients are now able to receive the most accurate diagnostics through the MRI Fusion software allowing for early and accurate treatment plans to be developed. Our patients are able to rely on expertise they can trust,” said Mediclinic Cape Town Hospital General Manager, Michelle Africa.
The Biojet system was developed by Dr Peter Klews, a physicist, who was also present at the most recent trial operation performed at Mediclinic Cape Town, and he will now modify the hardware and software to suit Dr Botha’s preferences.